Volume 5, Issue 11

Newer and Emerging MS Biomarkers

In this issue:

Biomarkers are critically needed tools in MS to quantify disease progression and burden and to monitor treatment effectiveness. What value have key newly available biomarkers — blood neurofilament light (NfL) and retinal layer thickness via optical coherence tomography (OCT) — added to caring for patients with MS? What does the emerging research show about emerging biomarkers like paramagnetic rim lesions (PRLs) and blood glial fibrillary acidic protein (GFAP)?

These are some of the questions addressed by Dr. Emily Schorr from the Department of Neurosciences at the University of California San Diego in this issue of eMultipleSclerosis Review.

Learning objectives:

  • Describe the strengths and limitations of the newer MS biomarkers currently available for clinical use.
  • Describe strengths and limitations of emerging biomarkers for progressive MS currently under investigation.

Author:

Emily Schorr, MD
Emily Schorr, MD

Assistant Professor of Neurosciences
University of California San Diego
La Jolla, CA

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: November 16, 2023
Expiration date: November 15, 2025